DOCSLIB.ORG

Recommendations for Lab Monitoring of Atypical Antipsychotics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recommendations for Lab Monitoring of Atypical Antipsychotics Savvy Psychopharmacology Recommendations for lab monitoring of atypical antipsychotics Kathryn Zeier, PharmD, Robert Connell, PharmD, BCPS, William Resch, DO, FAPA, and Christopher J. Thomas, PharmD, BCPS, BCPP, CGP r. H, age 31, is admitted to an acute well established.2 Over time, these effects psychiatric unit with major depres- can lead to metabolic syndrome, poor car- Msive disorder, substance dependence, diovascular outcome, and type 2 diabetes insomnia, and generalized anxiety. In the past, mellitus. Each drug has its own risk pro- he was treated unsuccessfully with sertraline, file, but all atypical antipsychotics have fluoxetine, clonazepam, venlafaxine, and lith- been shown to cause some metabolic ad- ium. The treatment team starts Mr. H on que- verse effects to a varying degree.3-5 A dose- tiapine, titrated to 150 mg at bedtime, to ad- effect relationship, if present, is estimated Vicki L. Ellingrod, dress suspected bipolar II disorder. to be small, and metabolic effects can oc- PharmD, FCCP At baseline, Mr. H is 68 inches tall and slightly cur at low dosages. Weight gain and other Series Editor overweight at 176 lbs (body mass index [BMI] metabolic effects are seen most strikingly 26.8 kg/m2). The laboratory reports his glycat- in patients who are antipsychotic-naïve, 3,4,6 ed hemoglobin (HbA1c) at 5.4%; low-density and in children and adolescents. No lipoprotein (LDL), 60 mg/dL; total cholesterol, antipsychotic should be considered body 122 mg/dL; triglycerides, 141 mg/dL; and high- density lipoprotein (HDL), 34 mg/dL. Within 1 month, Mr. H experiences a 16% in- Practice Points • All atypical antipsychotics carry a risk crease in body weight. HbA1c increases to 5.6%; LDL, to 93 mg/dL. These metabolic changes are of metabolic disturbance; clozapine and olanzapine have the highest risk, followed not addressed, and he continues quetiapine for by quetiapine and risperidone. another 5 months. At the end of 6 months, Mr. H weighs 223.8 lbs (BMI 34 kg/m2)—a 27% increase • Newer atypical antipsychotics may carry less of a risk of metabolic side effects, but from baseline. HbA is in the prediabetic range, 1c long-term data are lacking. at 5.9%, and LDL is 120 mg/dL.1 The treatment team discusses the risks of further metabolic • Obtain baseline and periodic monitoring of BMI, waist circumference, HbA , fasting effects, cardiovascular disease, and diabetes with 1c plasma glucose, and fasting lipids. Mr. H. He agrees to a change in therapy. • If you find an abnormality of any of these The association between atypical antipsy- parameters, consider one or more of the following: switching to an agent that is less chotics and metabolic adverse effects is risky; decreasing the dose or discontinuing Drs. Zeier and Connell are Second-Year Pharmacy Residents therapy; recommending diet and exercise; in Psychiatry, Dr. Resch is Director of Osteopathic Psychiatric Residency Program, and Dr. Thomas is Clinical Associate Professor and referring the patient to a program or of Pharmacology, Ohio University College of Osteopathic Medicine, clinician with expertise in the management Chillicothe Veterans Affairs Medical Center, Chillicothe, Ohio. of weight, diabetes, or lipids. Disclosure The authors report no financial relationships with any of the • Use monotherapy when appropriate to manufacturers mentioned in this article or with manufacturers of decrease the risk of side effects. Current Psychiatry competing products. Vol. 12, No. 9 51 Savvy Psychopharmacology Table 1 Comparison of metabolic effects of atypical antipsychotics Drug Weight gain Dyslipidemia Hyperglycemia Clozapine +++ +++ +++ Olanzapine +++ +++ +++ Risperidone ++ + + Quetiapine ++ ++ ++ Ziprasidone +/0 +/0 +/0 Aripiprazole +/0 +/0 +/0 Iloperidonea ++ +/0 +/0 Paliperidone + + + Clinical Point Asenapinea +/0 +/0 +/0 Clozapine and Lurasidonea +/0 +/0 +/0 olanzapine pose +++: significant; ++: intermediate; +: low; +/0: low or neutral aLimited data and/or long-term data are not available the highest risk Source: References 5,7 of weight gain; aripiprazole and ziprasidone present weight-neutral because all have the po- Newer atypical antipsychotics, such as the lowest risk tential for significant weight gain (>7% in asenapine, iloperidone, paliperidone, and body weight).3,4 lurasidone, seem to have a lower meta- An increase in weight is thought to be bolic risk profile, similar to those seen with associated with the actions of antipsychot- aripiprazole and ziprasidone.5 Patients 7 ics on H1 and 5-HT2c receptors. Clozapine enrolled in initial clinical trials might not and olanzapine pose the highest risk of be antipsychotic naïve, however, and may weight gain. Quetiapine and risperidone have been taking a high metabolic risk are considered of intermediate risk; aripip- antipsychotic. When these patients are razole and ziprasidone present the lowest switched to an antipsychotic that carries risk (Table 1).5,7 less of a metabolic risk, it might appear Patients taking an atypical antipsychotic that they are experiencing a decrease in may experience an elevation of blood glu- metabolic adverse events. cose, serum triglyceride, and LDL levels, and Metabolic data on newer atypical an- a decrease in the HDL level.2 These effects tipsychotics are limited; most have not may be seen without an increase in BMI, and been subject to long-term study. Routine should be considered a direct effect of the monitoring of metabolic side effects is rec- antipsychotic.5 Although the mechanism by ommended for all atypical antipsychotics, which dyslipidemia occurs is poorly under- regardless of risk profile. stood, an increase in the blood glucose level is thought to be, in part, mediated by antago- Recommended monitoring Discuss this article at nism of M3 muscarinic receptors on pancre- Because of the known metabolic side effects www.facebook.com/ atic β-cells.7 Clozapine and olanzapine pose that occur in patients taking an atypical an- CurrentPsychiatry the highest risk of dyslipidemia. Quetiapine tipsychotic, baseline and periodic monitor- and risperidone are considered of intermedi- ing is recommended (Table 2).2,10 BMI and ate risk; the risk associated with quetiapine waist circumference should be recorded at is closer to that of olanzpine.8,9 Aripiprazole baseline and tracked throughout treatment. and ziprasidone present a lower risk of dys- Ideally, obtain measurements monthly for Current Psychiatry 52 September 2013 lipidemia and glucose elevations.5 the first 3 months of therapy, or after any Savvy Psychopharmacology Table 2 Recommended monitoring for a patient taking an atypical antipsychotic Parameter Baseline 1 Mo 2 Mo 3 Mo 6 Mo Annually Body mass indexa X X X X X X Waist circumference X X X X X X b HbA1c X X X Fasting plasma glucose X X X Fasting lipid panel X X X aEncourage patients to monitor their weight in addition to being weighed at the clinic bUnless patient develops diabetes mellitus, in which case American Diabetes Association guidelines for managing diabetes are recommended Source: References 2,10 Clinical Point Record BMI and waist circumference medication adjustments, then at 6 months, health care professional or to a program of patients taking and annually thereafter. Encourage patients with expertise in weight management also atypicals at to track their own weight. might be beneficial.2 Include family mem- baseline and track HbA and fasting plasma glucose lev- bers and significant others in the patient’s 1c them throughout els should be measured at baseline and education when possible. throughout the course of treatment. Obtain treatment another set of measurements at 3 months, Impaired fasting glucose. Encourage a then annually thereafter, unless the patient low-carbohydrate, high-protein diet with develops type 2 diabetes mellitus.2 high intake of vegetables. Patients should Obtaining a fasting lipid panel at base- obtain at least 30 minutes of physical ac- line and periodically throughout the tivity, five times a week. Referral to a dia- course of treatment is recommended. After betes self-management class also is appro- baseline measurement, another panel priate. Consider referral to a primary care should be taken at 3 months and annu- physician or a clinician with expertise in ally thereafter. Guidelines of the American diabetes.2 Diabetes Association recommend a fasting lipid panel every 5 years—however, good Impaired fasting lipids. Encourage your clinical practice dictates obtaining a lipid patients to adhere to a heart-healthy diet panel annually. that is low in saturated fats and to get ad- equate physical activity. Referral to a dieti- Managing metabolic side effects cian and primary care provider for medi- Assess whether the patient can benefit cal management of dyslipidemia might be from a lower dosage of current medica- appropriate.2 tion, switching to an antipsychotic with less of a risk of metabolic disturbance, or References 1. American Diabetes Association. Executive summary: standards from discontinuation of therapy. In most of medical care in diabetes—2010. Diabetes Care. 2010;33: cases, aim to use monotherapy because S4-S10. polypharmacy contributes to an increased 2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, risk of side effects.10 and the North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601. Weight management. Recommend nutri- 3. Kahn RS, Fleischhacker WW, Boter
Load more

Recommended publications
  • Aripiprazole As an Adjunct to Anti-Depressants for Major Depressive Disorder: Clinical Effectiveness, Cost-Effectiveness, and Guidelines
    TITLE: Aripiprazole as an Adjunct to Anti-Depressants for Major Depressive Disorder: Clinical Effectiveness, Cost-Effectiveness, and Guidelines DATE: 04 May 2016 RESEARCH QUESTIONS 1. What is the clinical efficacy of aripiprazole as an adjunct to antidepressants for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments? 2. What is the cost-effectiveness of aripiprazole as an adjunct to antidepressants for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments? 3. What are the evidence-based guidelines for the use of aripiprazole for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments? KEY FINDINGS Three systematic reviews with meta-analyses, two randomized controlled trials, and two evidence-based guidelines were identified regarding the use of aripiprazole as an adjunct to antidepressants for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments. METHODS A limited literature search was conducted on key resources including PubMed, Ovid PsychINFO, Ovid Embase, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No methodological filters were used to limit retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2014 and April 29, 2016. Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada.
    [Show full text]
  • Aristada™ (Aripiprazole Lauroxil)
    Aristada™ (aripiprazole lauroxil) – New Drug Approval • On October 5, 2015, Alkermes’ announced the FDA approval of Aristada (aripiprazole lauroxil) extended-release injection, an atypical antipsychotic, for the treatment of schizophrenia. • Schizophrenia is a chronic, severe and disabling brain disorder affecting an estimated 2.4 million Americans. Typically, symptoms include hearing voices, believing other people are reading their minds or controlling their thoughts, and being suspicious or withdrawn. • Aristada’s approval was based on data from a double-blind, placebo-controlled 12-week trial involving 622 patients with schizophrenia. In addition, the efficacy of Aristada was established, in part, on the basis of efficacy data from trials with oral aripiprazole. — Aristada significantly improved symptoms of schizophrenia compared to placebo at day 85. • Similar to other atypical antipsychotics, Aristada carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis. • Other warnings and precautions for Aristada include cerebrovascular adverse reactions, including stroke; neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes; orthostatic hypotension; leukopenia, neutropenia, and agranulocytosis; seizures; potential for cognitive and motor impairment; body temperature regulation; and dysphagia. • The most common adverse reaction (≥ 5% and at least twice that for placebo) with Aristada use was akathisia. • Aristada is administered by intramuscular injection in the deltoid (441 mg dose only) or gluteal (441 mg, 662 mg, or 882 mg) muscle by a healthcare professional. — Aristada can be initiated at a monthly dose (441 mg, 662 mg or 882 mg) or every 6 week dose (882 mg). — For patients naïve to aripiprazole, tolerability should be established with oral aripiprazole prior to initiating treatment with Aristada.
    [Show full text]
  • When Clozapine Is Not Tolerated Mitchell J
    University of North Dakota UND Scholarly Commons Nursing Capstones Department of Nursing 10-28-2018 When Clozapine is Not Tolerated Mitchell J. Relf Follow this and additional works at: https://commons.und.edu/nurs-capstones Recommended Citation Relf, Mitchell J., "When Clozapine is Not Tolerated" (2018). Nursing Capstones. 268. https://commons.und.edu/nurs-capstones/268 This Independent Study is brought to you for free and open access by the Department of Nursing at UND Scholarly Commons. It has been accepted for inclusion in Nursing Capstones by an authorized administrator of UND Scholarly Commons. For more information, please contact [email protected]. Running head: WHEN CLOZAPINE IS NOT TOLERATED 1 WHEN CLOZAPINE IS NOT TOLERATED by Mitchell J. Relf Masters of Science in Nursing, University of North Dakota, 2018 An Independent Study Submitted to the Graduate Faculty of the University of North Dakota in partial fulfillment of the requirements for the degree of Master of Science Grand Forks, North Dakota December 2018 WHEN CLOZAPINE IS NOT TOLERATED 2 PERMISSION Title When Clozapine is Not Tolerated Department Nursing Degree Master of Science In presenting this independent study in partial fulfillment of the requirements for a graduate degree from the University of North Dakota, I agree that the College of Nursing and Professional Disciplines of this University shall make it freely available for inspection. I further agree that permission for extensive copying or electronic access for scholarly purposes may be granted by the professor who supervised my independent study work or, in her absence, by the chairperson of the department or the dean of the School of Graduate Studies.
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH PrFLUANXOL® Flupentixol Tablets (as flupentixol dihydrochloride) 0.5 mg, 3 mg, and 5 mg PrFLUANXOL® DEPOT Flupentixol Decanoate Intramuscular Injection 2% and 10% flupentixol decanoate Antipsychotic Agent Lundbeck Canada Inc. Date of Revision: 2600 Alfred-Nobel December 12th, 2017 Suite 400 St-Laurent, QC H4S 0A9 Submission Control No : 209135 Page 1 of 35 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................10 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION ..............................................................................15 OVERDOSAGE ................................................................................................................18 ACTION AND CLINICAL PHARMACOLOGY ............................................................19 STORAGE AND STABILITY ..........................................................................................21
    [Show full text]
  • Download Executive Summary
    Comparative Effectiveness Review Number 43 Effective Health Care Program Off-Label Use of Atypical Antipsychotics: An Update Executive Summary Background Effective Health Care Program Antipsychotics medications are approved The Effective Health Care Program by the U.S. Food and Drug Administration was initiated in 2005 to provide valid (FDA) for treatment of schizophrenia and evidence about the comparative bipolar disorder. These medications are effectiveness of different medical commonly divided into two classes, interventions. The object is to help reflecting two waves of historical consumers, health care providers, and development: the conventional others in making informed choices antipsychotics and the atypical. The among treatment alternatives. Through conventional antipsychotics served as the its Comparative Effectiveness Reviews, first successful pharmacologic treatment the program supports systematic for primary psychotic disorders such as appraisals of existing scientific schizophrenia. Having been widely used evidence regarding treatments for for decades, the conventional high-priority health conditions. It also antipsychotics also produced various side promotes and generates new scientific effects requiring additional medications, evidence by identifying gaps in which spurred the development of the existing scientific evidence and atypical antipsychotics. supporting new research. The program Currently, nine atypical antipsychotic drugs puts special emphasis on translating have been approved by FDA: aripiprazole, findings into a variety of useful asenapine, clozapine, iloperidone, formats for different stakeholders, olanzapine, paliperidone, quetiapine, including consumers. risperidone, and ziprasidone. These drugs The full report and this summary are have been used off-label (i.e., for available at www.effectivehealthcare. indications not approved by FDA) for the ahrq.gov/reports/final.cfm. treatment of various psychiatric conditions.
    [Show full text]
  • Lurasidone (Latuda) Reference Number: CP.PMN.50 Effective Date: 09.01.15 Last Review Date: 02.21 Line of Business: Commercial, HIM, Medicaid Revision Log
    Clinical Policy: Lurasidone (Latuda) Reference Number: CP.PMN.50 Effective Date: 09.01.15 Last Review Date: 02.21 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Lurasidone (Latuda®) is an atypical antipsychotic. FDA Approved Indication(s) Latuda is indicated for the treatment of: • Schizophrenia in adults and adolescents (13 to 17 years) • Depressive episode associated with bipolar I disorder (bipolar depression) in adults and pediatric patients (10 to 17 years) as monotherapy • Depressive episode associated with bipolar I disorder (bipolar depression) in adults as adjunctive therapy with lithium or valproate Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Latuda is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Bipolar Disorder (must meet all): 1. Diagnosis of bipolar disorder; 2. Age ≥ 10 years; 3. Failure of two preferred atypical antipsychotics (e.g., aripiprazole, ziprasidone, quetiapine, risperidone, or olanzapine) at up to maximally indicated doses, each used for ≥ 4 weeks, unless all are contraindicated or clinically significant adverse effects are experienced; 4. Dose does not exceed 120 mg per day for adults and 80 mg per day for pediatric patients. Approval duration: Medicaid/HIM – 12 months Commercial – Length of Benefit B. Schizophrenia (must meet all): 1. Diagnosis of schizophrenia; 2. Age ≥ 13 years; 3. Failure of two preferred atypical antipsychotics (e.g., aripiprazole, ziprasidone, quetiapine, risperidone, or olanzapine) at up to maximally indicated doses, each used Page 1 of 6 CLINICAL POLICY Lurasidone for ≥ 4 weeks, unless all are contraindicated or clinically significant adverse effects are experienced; 4.
    [Show full text]
  • Modern Antipsychotic Drugs: a Critical Overview
    Review Synthèse Modern antipsychotic drugs: a critical overview David M. Gardner, Ross J. Baldessarini, Paul Waraich Abstract mine was based primarily on the finding that dopamine ago- nists produced or worsened psychosis and that antagonists CONVENTIONAL ANTIPSYCHOTIC DRUGS, used for a half century to treat were clinically effective against psychotic and manic symp- a range of major psychiatric disorders, are being replaced in clini- 5 toms. Blocking dopamine D2 receptors may be a critical or cal practice by modern “atypical” antipsychotics, including ari- even sufficient neuropharmacologic action of most clinically piprazole, clozapine, olanzapine, quetiapine, risperidone and effective antipsychotic drugs, especially against hallucina- ziprasidone among others. As a class, the newer drugs have been promoted as being broadly clinically superior, but the evidence for tions and delusions, but it is not necessarily the only mecha- this is problematic. In this brief critical overview, we consider the nism for antipsychotic activity. Moreover, this activity, and pharmacology, therapeutic effectiveness, tolerability, adverse ef- subsequent pharmacocentric and circular speculations about fects and costs of individual modern agents versus older antipsy- altered dopaminergic function, have not led to a better un- chotic drugs. Because of typically minor differences between derstanding of the pathophysiology or causes of the several agents in clinical effectiveness and tolerability, and because of still idiopathic psychotic disorders, nor have they provided a growing concerns about potential adverse long-term health conse- non-empirical, theoretical basis for the design or discovery quences of some modern agents, it is reasonable to consider both of improved treatments for psychotic disorders. older and newer drugs for clinical use, and it is important to inform The neuropharmacodynamics of specific modern anti- patients of relative benefits, risks and costs of specific choices.
    [Show full text]
  • Medication Conversion Chart
    Fluphenazine FREQUENCY CONVERSION RATIO ROUTE USUAL DOSE (Range) (Range) OTHER INFORMATION KINETICS Prolixin® PO to IM Oral PO 2.5-20 mg/dy QD - QID NA ↑ dose by 2.5mg/dy Q week. After symptoms controlled, slowly ↓ dose to 1-5mg/dy (dosed QD) Onset: ≤ 1hr 1mg (2-60 mg/dy) Caution for doses > 20mg/dy (↑ risk EPS) Cmax: 0.5hr 2.5mg Elderly: Initial dose = 1 - 2.5mg/dy t½: 14.7-15.3hr 5mg Oral Soln: Dilute in 2oz water, tomato or fruit juice, milk, or uncaffeinated carbonated drinks Duration of Action: 6-8hr 10mg Avoid caffeinated drinks (coffee, cola), tannics (tea), or pectinates (apple juice) 2° possible incompatibilityElimination: Hepatic to inactive metabolites 5mg/ml soln Hemodialysis: Not dialyzable HCl IM 2.5-10 mg/dy Q6-8 hr 1/3-1/2 po dose = IM dose Initial dose (usual): 1.25mg Onset: ≤ 1hr Immediate Caution for doses > 10mg/dy Cmax: 1.5-2hr Release t½: 14.7-15.3hr 2.5mg/ml Duration Action: 6-8hr Elimination: Hepatic to inactive metabolites Hemodialysis: Not dialyzable Decanoate IM 12.5-50mg Q2-3 wks 10mg po = 12.5mg IM CONVERTING FROM PO TO LONG-ACTING DECANOATE: Onset: 24-72hr (4-72hr) Long-Acting SC (12.5-100mg) (1-4 wks) Round to nearest 12.5mg Method 1: 1.25 X po daily dose = equiv decanoate dose; admin Q2-3wks. Cont ½ po daily dose X 1st few mths Cmax: 48-96hr 25mg/ml Method 2: ↑ decanoate dose over 4wks & ↓ po dose over 4-8wks as follows (accelerate taper for sx of EPS): t½: 6.8-9.6dy (single dose) ORAL DECANOATE (Administer Q 2 weeks) 15dy (14-100dy chronic administration) ORAL DOSE (mg/dy) ↓ DOSE OVER (wks) INITIAL DOSE (mg) TARGET DOSE (mg) DOSE OVER (wks) Steady State: 2mth (1.5-3mth) 5 4 6.25 6.25 0 Duration Action: 2wk (1-6wk) Elimination: Hepatic to inactive metabolites 10 4 6.25 12.5 4 Hemodialysis: Not dialyzable 20 8 6.25 12.5 4 30 8 6.25 25 4 40 8 6.25 25 4 Method 3: Admin equivalent decanoate dose Q2-3wks.
    [Show full text]
  • Adjunctive Risperidone Treatment for Antidepressant-Resistant
    Supplementary Online Content Krystal JH, Rosenheck RA, Cramer JA, et al. Adjunctive risperidone treatment for antidepressant- resistant symptoms of chronic military service–related PTSD. JAMA. 2011;306(5):493-502. eTable 1. Follow-up Drugs Started After Randomization eTable 2. Baseline Medications eTable 3. Number of Different Drugs From Each Major Class Each Patient Is Taking at Baseline eTable 4. Baseline Medication Combinations eTable 5. Adverse Events eFigure 1. Product-Limit Survival Estimates With Number of Subjects at Risk eFigure 2. Percentage of Veterans at Each CAPS Severity Level at 24 Weeks, by Treatment This supplementary material has been provided by the authors to give readers additional information about their work. © 2011 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/23/2021 eTable 1. Follow-up Drugs Started After Randomization Placebo Risperidone N= 134 N= 133 Total Patients % Patients % Patients % p-value Drugs started after randomization 46 34.3 59 44.4 105 39.3 0.10 Adrenergic Drugs 4 3.0 5 3.8 9 3.4 0.75 Atenolol 0 0.0 2 1.5 2 0.7 Metoprolol 3 2.2 2 1.5 5 1.9 Propranolol 1 0.7 1 0.8 2 0.7 Opiates 22 16.4 19 14.3 41 15.4 0.73 Codeine 1 0.7 1 0.8 2 0.7 Fentanyl 3 2.2 0 0.0 3 1.1 Hydrocodone (With Or Without 13 9.7 10 7.5 23 8.6 Acetaminophen) Methadone 1 0.7 0 0.0 1 0.4 Morphine 3 2.2 2 1.5 5 1.9 Oxycodone (With Or Without 4 3.0 7 5.3 11 4.1 Acetaminophen) Tramadol 3 2.2 2 1.5 5 1.9 Psycho-Stimulants 0 0.0 2 1.5 2 0.7 0.25 Methylphenidate 0 0.0 2 1.5 2 0.7 Muscle
    [Show full text]
  • Management of Side Effects of Antipsychotics
    Management of side effects of antipsychotics Oliver Freudenreich, MD, FACLP Co-Director, MGH Schizophrenia Program www.mghcme.org Disclosures I have the following relevant financial relationship with a commercial interest to disclose (recipient SELF; content SCHIZOPHRENIA): • Alkermes – Consultant honoraria (Advisory Board) • Avanir – Research grant (to institution) • Janssen – Research grant (to institution), consultant honoraria (Advisory Board) • Neurocrine – Consultant honoraria (Advisory Board) • Novartis – Consultant honoraria • Otsuka – Research grant (to institution) • Roche – Consultant honoraria • Saladax – Research grant (to institution) • Elsevier – Honoraria (medical editing) • Global Medical Education – Honoraria (CME speaker and content developer) • Medscape – Honoraria (CME speaker) • Wolters-Kluwer – Royalties (content developer) • UpToDate – Royalties, honoraria (content developer and editor) • American Psychiatric Association – Consultant honoraria (SMI Adviser) www.mghcme.org Outline • Antipsychotic side effect summary • Critical side effect management – NMS – Cardiac side effects – Gastrointestinal side effects – Clozapine black box warnings • Routine side effect management – Metabolic side effects – Motor side effects – Prolactin elevation • The man-in-the-arena algorithm www.mghcme.org Receptor profile and side effects • Alpha-1 – Hypotension: slow titration • Dopamine-2 – Dystonia: prophylactic anticholinergic – Akathisia, parkinsonism, tardive dyskinesia – Hyperprolactinemia • Histamine-1 – Sedation – Weight gain
    [Show full text]
  • Current P SYCHIATRY
    Current p SYCHIATRY N ew Investigators Tips to manage and prevent discontinuation syndromes Informed tapering can protect patients when you stop a medication Sriram Ramaswamy, MD Shruti Malik, MBBS, MHSA Vijay Dewan, MD Instructor, department of psychiatry Foreign medical graduate Assistant professor Creighton University Department of psychiatry Omaha, NE University of Nebraska Medical Center Omaha, NE bruptly stopping common psychotropics New insights on psychotropic A —particularly antidepressants, benzodi- drug safety and side effects azepines, or atypical antipsychotics—can trigger a discontinuation syndrome, with: This paper was among those entered in the 2005 • rebound or relapse of original symptoms Promising New Investigators competition sponsored • uncomfortable new physical and psycho- by the Neuroleptic Malignant Syndrome Information Service (NMSIS). The theme of this year’s competition logical symptoms was “New insights on psychotropic drug safety and • physiologic withdrawal at times. side effects.” To increase health professionals’ awareness of URRENT SYCHIATRY 1 C P is honored to publish this peer- the risk of these adverse effects, this article reviewed, evidence-based article on a clinically describes discontinuation syndromes associated important topic for practicing psychiatrists. with various psychotropics and offers strategies to NMSIS is dedicated to reducing morbidity and anticipate, recognize, and manage them. mortality of NMS by improving medical and psychiatric care of patients with heat-related disorders; providing
    [Show full text]
  • Guidance on Strategies to Promote Best Practice in Antipsychotic Prescribing for Children and Adolescents
    Acknowledgments This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) under contract number HHSS2832017000751/HHSS28342001T with SAMHSA, U.S. Department of Health and Human Services (HHS), in consultation with Thomas I. Mackie, Ph.D., M.P.H. Nadine Benton served as contracting officer representative with Stacey Lee as the task lead. Disclaimer The views, opinions, and content of this publication are those of the author and do not necessarily reflect the views, opinions, or policies of SAMHSA or HHS. Nothing in this document constitutes a direct or indirect endorsement by SAMHSA or HHS of any non‐Federal entity’s products, services, or policies, and any reference to non‐Federal entity’s products, services, or policies should not be construed as such. Public Domain Notice All material appearing in this publication is in the public domain and may be reproduced or copied without permission from SAMHSA. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA, HHS. Electronic Access This publication may be downloaded from http://store.samhsa.gov. Recommended Citation Substance Abuse and Mental Health Services Administration: Guidance on Strategies to Promote Best Practice in Antipsychotic Prescribing for Children and Adolescents. HHS Publication No. PEP19‐ ANTIPSYCHOTIC‐BP. Rockville, MD: Office of Chief Medical Officer. Substance Abuse and Mental Health Services Administration, 2019. Originating Office Office of Behavioral Health Equity and Office of Chief Medical Officer, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857, HHS Publication No.
    [Show full text]